The study NCT02859077 is designed to explore an EGFR-TKI (gefitinib) in combination with chemotherapy as first-line treatment in stage IIIB/IV NSCLC patients with both EGFR mutation and BIM deletion polymorphism. This evidence concerns the gene EGFR and non-small cell lung carcinoma.